in the liver function and hepatitis B virus reactivation
was withdrawn and isotonic saline infusion was commenced.
Results strongly suggest that bortezomib
treatment enhanced T cell death by inhibiting NF-kappa B activation, which plays a key role in regulating the immune response to infection.
Elotuzumab was found to work in synergy with bortezomib
in a pre-clinical model, which served as the basis for this clinic trial.
They provide excellent pre-clinical rationale for expanding the use of ACY-1215 in combination with bortezomib
for patients with relapsed or refractory lymphoma.
This regulatory submission is based on data from the company's Phase 3 ALCYONE (MMY3007) study of DARZALEX in combination with bortezomib
, melphalan and prednisone in frontline multiple myeloma.
1 Ninety-eight percent of patients received prior bortezomib
treatment and 33 percent of patients received prior carfilzomib treatment.
According to the company, this submission is based on data from the Phase III ALCYONE study of daratumumab in combination with bortezomib
, melphalan and prednisone in front line multiple myeloma.
Contract award notice:Supply of the drug whose active ingredient is Bortezomib
, destined to the Assistance Complexes of vila, Len, Salamanca, Segovia, Soria and Zamora and Hospitales Santiago Apstol de Miranda de Ebro, Santos Reyes de Aranda de Duero, Bierzo Hospital, Ro Hortega University, University Clinic of Valladolid.
announce the publication of a research article entitled "A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib
Resistance" (Chauhan et al, Cancer Cell).
This application seeks to expand the current indication, using Darzalex in combination with bortezomib
(a proteasome inhibitor [PI]), melphalan and prednisone, for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Janssen Research & Development, LLC today announced new data from updated analyses of the pivotal Phase 3 CASTOR and POLLUX clinical studies, demonstrating that DARZALEX (daratumumab) in combination with bortezomib
and dexamethasone, or lenalidomide and dexamethasone, improved progression-free survival (PFS) and the overall response rate (ORR) for previously-treated patients with multiple myeloma, regardless of cytogenetic risk.
Senesco" or the "Company") (NYSE MKT: SNT) announced today that the combination of bortezomib
(the active component of VELCADE([R])marketed by Millennium, The Takeda Oncology Company) and SNS01-T, the subject of Senesco's on-going multiple myeloma clinical study, performs significantly better than either treatment alone in mouse xenograft models.
Janssen-Cilag International NV (Janssen) today announced that the European Commission (EC) has granted approval to DARZALEX (daratumumab) for use in combination with lenalidomide and dexamethasone, or bortezomib
(VELCADE) and dexamethasone, for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.
The randomized ENDEAVOR (RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib
Plus DexamethasOne in Patients With Relapsed Multiple Myeloma) trial of 929 patients evaluated Kd56 versus Vd in patients whose multiple myeloma has relapsed after at least one, but not more than three prior therapeutic regimens.